StockData
Contineum Therapeutics, Inc. logo

Contineum Therapeutics, Inc. (CTNM) stock

CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$9.24−0.31 (-3.25%)

Close on Nov 18, 2026Market cap $347.62MP/E –Yield –

Contineum Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Contineum Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $0, down 100.0% year over year. For fiscal 2024 it was $0, down 100.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2024Dec 31, 2024$0-100.0%
FY2023Dec 31, 2023$50.00M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$0-100.0%
Q2 FY2024Jun 30, 2024$0–
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$0–
Q2 FY2023Jun 30, 2023$50.00M–

More Contineum Therapeutics figures

See a number that looks wrong?